The CD40-CD40L axis: Current and future implications in clinical immunology [L'axe CD40-CD40L : implications actuelles et futures en immunologie clinique]
DUFFAU, Pierre
Composantes innées de la réponse immunitaire et différenciation [CIRID]
Service de médecine interne et maladies infectieuses [Bordeaux]
Hôpital Saint-André [Bordeaux]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Hôpital Saint-André
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
Composantes innées de la réponse immunitaire et différenciation [CIRID]
Service de médecine interne et maladies infectieuses [Bordeaux]
Hôpital Saint-André [Bordeaux]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Hôpital Saint-André
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
DUFFAU, Pierre
Composantes innées de la réponse immunitaire et différenciation [CIRID]
Service de médecine interne et maladies infectieuses [Bordeaux]
Hôpital Saint-André [Bordeaux]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Hôpital Saint-André
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
< Réduire
Composantes innées de la réponse immunitaire et différenciation [CIRID]
Service de médecine interne et maladies infectieuses [Bordeaux]
Hôpital Saint-André [Bordeaux]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Hôpital Saint-André
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
Langue
FR
Article de revue
Ce document a été publié dans
Revue de Medecine Interne. 2021, vol. 42, n° 10, p. 722-728
Résumé en anglais
The CD40-CD40 ligand (CD40L) pathway is a backbone of communication between cells of the immune system. It makes it possible to generate a proinflammatory signal and thus participates in the pathogenesis of dysimmune ...Lire la suite >
The CD40-CD40 ligand (CD40L) pathway is a backbone of communication between cells of the immune system. It makes it possible to generate a proinflammatory signal and thus participates in the pathogenesis of dysimmune diseases, transplant rejection and atherosclerosis. Because of this therapeutic target of choice, several generations of anti-CD40L monoclonal antibodies have emerged since the 1990s. The first generation of antibodies was responsible for thromboembolic toxicity for which the mechanisms are starting to be defined. New generations of antibodies were designed to overcome this toxicity and are still being developed in lupus, rheumatoid arthritis, Sjogren's syndrome or immunologic thrombocytopenia. In addition to these targeted therapies, there are data suggesting the impact of several drugs among molecules used in cardiology and clinical immunology on the level of CD40L. The objective of this review is to recall the clinical issues related to the CD40-CD40L axis and to present current or future treatments that block CD40L which would allow clinicians to diversify their options for managing dysimmune diseases.< Réduire
Mots clés en anglais
Autoimmunity
CD40 ligand
Inflammation
Monoclonal antibody
Targeted therapy
Unités de recherche